letermovir (Compound)

Synonyms:Letermovir, 917389-32-3, AIC246, Prevymis, AIC-246, MK-8228, AIC 246, 1H09Y5WO1F, 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic acid, 4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-(4-(3-methoxyphenyl)-1-piperazinyl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-, (4S)-, (S)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid, Letermovir [INN], Letermovir [USAN:INN], UNII-1H09Y5WO1F, Prevymis (TN), (S)-[8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl]acetic acid, (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl}acetic acid, MK-8828, Letermovir(AIC246), LETERMOVIR [MI], LETERMOVIR [JAN], LETERMOVIR [USAN], LETERMOVIR [WHO-DD], Letermovir (JAN/USAN/INN), SCHEMBL379403, CHEMBL1241951, LETERMOVIR [ORANGE BOOK], DTXSID40238683, EX-A1871, s8873, CS-1571, DB12070, AIC246;AIC 246;AIC-246, NCGC00378936-01, NCGC00378936-02, AC-35698, AS-56206, HY-15233, J3.556.145E, D10801, D71052, A902281, EN300-18167086, Q15409407, (4S)-2-{8-Fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid, (4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid, (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydro-quinazolin-4-yl}acetic acid, (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazolin-4-yl}acetic acid, 2-[(4S)-8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-yl]acetic acid

Pubchem:PUBCHEM:45138674

Id:7123064a-c9b7-5475-8464-058ae8aca210

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View letermovir's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for letermovir.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with letermovir.

Results found

Linked to

	Label	Description
	BRD-K94288301-001-01-7 Substance (Entity type)	A Substance
	DCSTRUCT ID 05262 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05262; PubChem_CID:45138674, FILE=drugcentral_drug_05262.json)
	letermovir (718e312c-475e-4d96-9926-f8e11d801f4d) Collection (Entity type)	Metadatata for letermovir
	letermovir negatively regulates SQOR Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	letermovir positively regulates AK4 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	letermovir in similarity relationship with Cianidanol Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	letermovir positively regulates CLEC11A Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	letermovir negatively regulates NR3C1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	letermovir positively regulates TF Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	letermovir negatively regulates TRAPPC3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS